Fusion Protein and Hybridoma

融合蛋白和杂交瘤

• 批准号: 8058776
• 负责人: Vadim V Deyev
• 金额: $ 9.44万
• 依托单位: UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8058776
• 关键词: Cell Separation; Cells; Chimeric Proteins; Generations; Hybridomas; In Vitro; Individual; Monoclonal Antibodies; Regulation; Research; Tumor Immunity; cost; design; design and construction; in vivo; novel; programs; research study

The Fusion Proteins and Monoclonal Antibodies Core will design, generate and purify fusion proteins and monoclonal antibodies for the Regulation of Tumor Immunity Program. The core in a cost-effective way will provide individual projects with large amounts of monoclonal antibodies and fusion proteins needed for plate coating, large scale cell separation in vitro, and cell blocking and depletion experiments in vivo. The core will also purify required amounts of monoclonal antibodies and fusion proteins unique for the proposed research, and generate and characterize new fusion proteins and hybridomas.

融合蛋白和单克隆抗体核心将设计，生成和纯化融合蛋白，并且 调节肿瘤免疫程序的单克隆抗体。以具有成本效益的方式的核心将 为单个项目提供大量的单克隆抗体和板块所需的融合蛋白 涂层，体外大规模细胞分离，并在体内进行细胞阻塞和耗竭实验。核心意愿 还纯化所需数量的单克隆抗体和融合蛋白，对于拟议的研究， 并产生和表征新的融合蛋白和杂交瘤。